The ALPS Medical Breakthroughs ETF is an exchange-traded fund specializing in equity securities in the biotechnology industry. Its primary function is to provide investors with exposure to small and mid-sized biotechnology companies that are on the cusp of major scientific breakthroughs. This ETF focuses on firms that have one or more drugs in the Phase II or Phase III stages of clinical trials, which are critical phases in the drug approval process. The ALPS Medical Breakthroughs ETF plays a crucial role in broadening investment in innovative health solutions and pharmaceuticals, catering primarily to sectors that encompass healthcare and biotech research. It acts as a significant vehicle for investing in emerging pharmaceutical companies that possess high potential for growth due to their drug development pipelines. By channeling funds into these sectors, the ETF aids in advancing medical research and innovation, while offering a structured yet diversified means for stakeholders to participate in the dynamic healthcare landscape.